Objectives: PYRRO-C3D is a cephalosporin-3-diazeniumdiolate nitric oxide (NO)-donor 29 prodrug designed to selectively deliver NO to bacterial infection sites. The objective of this 30 study was to assess the activity of PYRRO-C3D against non-typeable Haemophilus influenzae 31 (NTHi) biofilms and examine the role of NO in reducing biofilm-associated antibiotic 32 tolerance. 33 34
INTRODUCTION 60
Non-typeable Haemophilus influenzae (NTHi) plays a major role in a number of 61 chronic lung diseases, including chronic obstructive pulmonary disease, the fourth largest 62 cause of mortality worldwide [1] , and cystic fibrosis, where early childhood infection leads to 63 an environment within the lung that is more susceptible to infection by Pseudomonas 64 aeruginosa [2] . NTHi is also the predominant early coloniser in primary ciliary dyskinesia 65 (PCD), another genetic chronic lung disease characterised by a lack of mucociliary clearance, 66 chronic lung infection and lung function decline [3, 4] . 67
Persistence of NTHi infection is often associated with biofilm formation, with NTHi 68 biofilms being implicated in a number of clinical settings including formation on middle ear 69 epithelium during chronic otitis media [5] , chronic rhinosinusitis [6] , chronic obstructive 70 pulmonary disease (COPD) sputum [7] , and lower respiratory tract diseases [8] . The biofilm 71 phenotype enables bacteria to evade the host immune response, benefit from increased 72 antibiotic tolerance, and subsequently develop antibiotic resistance through horizontal gene 73 transfer [9] . Exopolysaccharide matrix formation by biofilm bacteria may also restrict the 74 diffusion of antibiotics into biofilms and prevent ingress of immune cells [10] . Increased 75 expression of efflux pumps and β-lactamases have also been shown to contribute to 76 increased tolerance. It is the change to a metabolically dormant phenotype, however, that 77 potentially plays the most important role, rendering antibiotics that target cell division 78 ineffective [11] . Biofilm formation in NTHi has been associated with the reduced metabolic 79 activity typical of that observed in other bacterial species, with preserved ability to respond 80 to stress [12] . As well as clinical isolates from a range of diseases having the ability to form in 81 vitro biofilms [8] , NTHi has also been shown to form biofilms on cultured respiratory 82 epithelial surfaces with decreased antibiotic susceptibility [13, 14] . NTHi biofilms also exhibit 83 quorum signalling that is characteristic of other respiratory biofilm formers such as P. 84 aeruginosa [15] . Whilst P. aeruginosa is the most widely studied biofilm forming respiratorypathogen, many differences exist with NTHi. For example, P. aeruginosa biofilms form 86 within mucus in vivo [16] rather than attached to the epithelial surface as NTHi biofilms do 87 [5, 6, 13, 14] . Also, cyclic-di-GMP seems to play a pivotal role in the P. aeruginosa biofilm life 88 cycle under the control of guanylate cyclases and phosphodiesterases [17] , however NTHi 89 genome sequencing shows no domains coding for these enzymes [18] . 90
Bacteria within biofilms can be triggered by various external factors to revert to a 91 planktonic single cell state, a process that not only facilitates propagation and re-92 colonisation elsewhere within the host but also renders the bacteria more susceptible to 93
antibiotics [10] . Development of a therapeutic approach that induces dispersal or reverses 94 the metabolically dormant phenotype is therefore an attractive approach for improving 95 antibiotic effectiveness in the treatment of biofilm-associated infections. 96
Nitric oxide (NO) is a ubiquitous signalling molecule that plays a wide range of 97 biological roles in both prokaryotes and eukaryotes. Low dose NO has been shown to signal 98 a dispersal response in biofilms formed by a number of bacterial species, including P. 99 aeruginosa, Escherichia coli, Serratia marcascens, Staphylococcus aureus, and also multi-100 species biofilms [19] [20] [21] . However, NO also plays a number of important roles in the human 101 host, meaning that administration of spontaneous NO donors as drugs would likely elicit 102 undesirable side effects, particularly through alterations in circulatory dynamics [22] [23] [24] . To 103 address this we have developed a novel class of targeted NO prodrugs (cephalosporin-3'-104 diazeniumdiolates) that are composed of a diazeniumdiolate (NONOate) NO-donor attached 105 to the 3'-position of first generation cephalosporins. This innovative drug class was designed 106 to selectively release the NONOate following cleavage of the β-lactam ring by bacterial β-107 lactamases, thereby targeting NO delivery directly to the site of infection [25] (Figure 1a) . 108
We hypothesised that treatment of NTHi biofilms with a cephalosporin-3'-diazeniumdiolate 109 (i.e. PYRRO-C3D K+ salt, Figure 1a ) would signal a return to a planktonic phenotype, thereby 110 increasing NTHi sensitivity towards conventional antibiotics. We investigated the activity ofPYRRO-C3D, both alone and in combination with azithromycin, on biofilms formed in vitro 112 and on primary respiratory epithelia grown at an air-liquid interface. High-throughput label-113 free proteomic analyses were performed to provide mechanistic insights into the role of NO 114 in NTHi biofilms. 115 116
MATERIALS AND METHODS 117

Ethics 118
Local and national R&D and ethical approvals were obtained (Southampton and South West 119
Hampshire Research Ethics 06/Q1704/105 and 07/Q1702/109). 120 121
Bacterial strains and growth conditions 122
NTHi strain HI4 was isolated from the sputum of a PCD patient. HI5 and HI6 were from nasal 123 swabs of healthy children participating in a nasal carriage study. All experiments were 124 performed using strain HI4 unless stated otherwise. HI4 and HI6 were β-lactamase 125 producing strains, whilst HI5 lacked β-lactamase activity. Strains were subcultured onto 126
Colombia agar with chocolated horse blood (CBA; Oxoid, U.K.) and grown at 37 o C and 5% 127 CO 2 . Colonies were resuspended in brain-heart infusion (BHI) broth (Oxoid, U.K.) 128 supplemented with 10 μg/mL hemin and 2 μg/mL nicotinamide adenine dinucleotide. 129 A minimum of 4 weeks after ciliation, trans-epithelial resistance was measured to confirm an 160 intact epithelial surface [28] . NTHi in MEM containing HEPES without glutamine 161 (ThermoFisher, U.K.) were applied to the apical surface of the epithelial cells at an MOI of 162 100:1. Co-cultures were grown for 72 h at 37 oC and 5% CO2 with the media changed every 163 24 h. Both the apical and baso-lateral surfaces were washed with HBSS prior to treatment. 164
Co-cultures were treated with compounds and processed for CFU enumeration as before. 165
Transwell membranes were removed, processed as previously described [29] , and remaining 166 biofilms imaged using an FEI Quanta 250 scanning electron microscope. 167 of 300 nL/min. All separations were automated, performed on-line and sprayed directly into 210 the nanospray source of the mass spectrometer. MS experiments were all performed using a 211
Waters G2-S Synapt HDMS mass spectrometer operating in MS e mode. Data were acquired 212 from 50 to 2000 m/z with ion mobility enabled using alternate low and high collision energy 213 (CE) scans. Low CE was 5V and elevated, ramped from 20-40V. The lock mass (Glufibrinopeptide, (M+2H) +2 , m/z = 785.8426) was infused at a concentration of 100 fmol/µL at 215 300 nl/min and spectra acquired every 13 seconds. 216 217
Identification of proteins from MS spectra 218
The raw mass spectra were processed using ProteinLynx Global Server Ver 3.0 (enabled 219 through Symphony pipeline software, Waters, U.K.) to generate a reduced charge state and 220 de-isotoped precursor lists, with associated product ion mass lists. These mass lists were 221 searched against the H. influenzae strain 3655 UniProt protein sequence (downloaded June 222 2016). A maximum of one missed cleavage was allowed for tryptic digestion and the allowed 223 variable modification was set to contain oxidation of methionine. Carboxyamidomethylation 224 of cysteine was set as a fixed modification. 225 226
Statistical analysis 227
Statistical analyses were performed using GraphPad version 6.04 and unpaired t-tests. Data 228 reported with a significance ≤0.05 were considered statistically different. Analysis of 229 identified proteins was corrected for multiple analysis using a false discovery rate (FDR) of 230 5%. Proteins that were either >1.5 or <0.7 fold changed following NO treatment were 231 analysed using the Kyoto Encyclopaedia of Genes and Genomes (KEGG) [31, 32] 
RESULTS 235
PYRRO-C3D elicits a direct antibacterial effect on planktonic but not biofilm NTHi 236
Prior to treatment of NTHi, NO release from PYRRO-C3D was first confirmed following 237 chemical activation by the β-lactamase enzyme penicillinase. Activation of 50 μM PYRRO-238 C3D resulted in rapid release of NO, reaching a maximum concentration of ~600 nM over 14 239 minutes, which was followed by a gradual decline over a further 120 minutes (Figure 1b) . azithromycin was also observed (p=0.0974; Figure 3c ). COMSTAT analysis also showed no 264 significant difference in biofilm thickness across any of the treatments, suggesting a lack of 265 biofilm dispersal (Figure 3d) . Measurement of biofilm density, assessed by average diffusiondistance between live bacteria, revealed that PYRRO-C3D alone increased biofilm density, 267 whereas treatment with azithromycin had no effect (Figure 4 ). Combination treatment with 268 azithromycin did, however, rescind the increase in biofilm density observed when treating 269 with PYRRO-C3D alone (Figure 4) . 270 271
Response of NTHi biofilms to PYRRO-C3D is NO-mediated 272
Having established that PYRRO-C3D potentiates the activity of azithromycin against NTHi 273 biofilms, experiments were next performed to examine whether the effect was NO-274 mediated. Treatment of biofilms with an equivalent concentration (50 μM) of the 275 spontaneous NO-donor DEA/NO alone had no effect on biofilm viability (p=1.08; Figure 5a ). 276
In contrast to the PYRRO-C3D/azithromycin combination, no increase in antibiotic efficacy 277 was observed when DEA/NO was co-administered with azithromycin (p=0.56; Figure 5a ). 278
Treatment with the NO-scavenger cPTIO nullified the increase in azithromycin susceptibility 279 observed in the presence of PYRRO-C3D (p=0.0001), suggesting that the potentiation effect 280 is NO-mediated but requires slower, more controlled release of NO than is achievable with 281 DEA/NO (Figure 5b) . Treatment with cephaloram, the parent 1 st generation cephalosporin 282 from which PYRRO-C3D is derived (but lacking an NO donor), also showed no effect on 283 biofilm viability in the absence or presence of azithromycin, suggesting that the potentiation 284 response with PYRRO-C3D does not arise from β-lactam-mediated antibacterial activity 285 (Figure 5a ). The β-lactamase inhibitor clavulanate abrogated the potentiation response, 286 consistent with NO release from PYRRO-C3D requiring β-lactamases (Figure 5b ). This finding 287 was corroborated by the absence of potentiation observed when treating a non-β-lactamase 288 producing strain (HI5) with PYRRO-C3D and azithromycin (p=0.24), whilst observing a strong 289 effect with an alternative β-lactamase producing strain HI6 (p<0.0001; Figure 6) . 290
PYRRO-C3D increases azithromycin susceptibility of NTHi biofilms grown on primary 292 respiratory epithelial cells 293 PYRRO-C3D treatment of NTHi biofilms formed on primary respiratory ciliated epithelial cells 294
at an air-liquid interface (ALI) was used to investigate whether the presence of human host 295 cells affected the activity of the compound. Lack of NO release from PYRRO-C3D in the 296 absence of NTHi cells was first confirmed, where NO release was detected only after 297 introduction of β-lactamase (Figure 7a ). Scanning electron microscopy (SEM) was used to 298 confirm NTHi biofilm formation following 72 h co-culture before proceeding with compound 299 treatments ( Figure 7c ). As observed in the in vitro NTHi-only biofilm model, treatment of the 300 co-cultures with PYRRO-C3D alone had no effect on viability (p=0.41) and treatment with 301 azithromycin alone resulted in a log-fold reduction (p=0.0007). When used in combination, 302 azithromycin and PYRRO-C3D produced a significant 2-log-fold reduction in viability relative 303 to controls (p=0.0026; Figure 7b) . 304 and that this release is specifically triggered by β-lactamases, as evidenced by the cessation 334 of NO release in the presence of the β-lactamase inhibitor clavulanate. These data, and the 335 lack of NO release when PYRRO-C3D was applied to respiratory epithelial cells in the 336 absence of NTHi, demonstrates the specificity of the prodrug activation by bacterial cells, an 337 attribute that would likely reduce the risk of NO-mediated side effects in vivo. 338
Regulation of the intracellular secondary messenger c-di-GMP plays a pivotal role in 339 controlling both biofilm formation and dispersal, with increased levels promoting formation 340 through increased aggregation, extracellular matrix and adhesin production, and reduced 341 levels signalling a dispersal response [35] [36] [37] . C-di-GMP levels are regulated by diguanylate 342 cyclases (containing GGDEF domains) that are responsible for its synthesis, and 343 phosphodiesterases (containing HD-GYP and EAL domains) that catalyse degradation [37] . and Staphylococcus epidermidis biofilms [42, 43] . Interestingly, MetQ is also linked to a 368 number of iron chelation/transporter proteins. It is known that iron can interfere with P. 369 aeruginosa biofilm formation by inhibiting genes associated with biofilm formation, whilst 370
SapF mediates heme utilisation and is involved in both biofilm persistence and coordination 371 [44, 45] . NO treatment of E. coli has also been shown to inhibit a global regulator (fur) that 372 uses iron as a co-factor, affecting a wide range of metabolic processes such as the stress 373 response and iron metabolism [46] and has been implicated in NTHi virulence [47] . 374
While several studies have shown that NO-mediated dispersal of biofilms reduces 375 antibiotic tolerance [19] [20] [21] , the regulation of pneumococcal biofilm metabolism was 376 recently shown to provide an alternative mechanism for reducing tolerance [33] . As PYRRO-377 C3D increases the susceptibility of NTHi biofilms to treatment with azithromycin, it is 378 possible that a similar mechanism to that observed in pneumococcus is also responsible for 379 reduction in tolerance observed here. Abrogation of the potentiation effect in the presence 380 of the β-lactamase inhibitor clavulanate and the NO-scavenger cPTIO, in addition to the lack 381 of response with cephaloram, confirmed that the response to PYRRO-C3D was indeed NOmediated. It is worth noting that treatment of a strain lacking β-lactamase activity failed to 383 potentiate the activity of azithromycin, suggesting that PYRRO-C3D would likely be effective 384 only against NTHi biofilms capable of β-lactamase production. 385
Observing a significant improvement in azithromycin efficacy when used alongside 386 PYRRO-C3D but not in the presence of an equivalent concentration of the spontaneous NO 387 donor DEA/NO suggests a bacteria-targeted NO-donor such as PYRRO-C3D would be more 388 effective in the treatment of biofilm-associated infections. Whilst the half-life of DEA/NO is 389 around 90 seconds, the release of NO from PYRRO-C3D continues for up to 120 minutes, 390
suggesting that slow but sustained release is beneficial. Moreover, it was particularly 391 noteworthy that NTHi biofilm susceptibility to combined PYRRO-C3D and azithromycin 392 treatment was even more pronounced when co-cultured on primary epithelial cells -a more 393 physiologically relevant model of biofilm infections in the respiratory tract. 394 395
CONCLUSION 396
In conclusion, this study has shown that the novel NO-donor prodrug PYRRO-C3D is effective 397 in specifically targeting NO release to β-lactamase producing NTHi biofilms, and that through 398 modulation of metabolic activity, the compound potentiates the antibacterial activity of 399 azithromycin. This effect is not seen in the absence of β-lactamase production. PYRRO-C3D 400 used in combination with azithromycin thus warrants further investigation as a potential 401 treatment for chronic, biofilm-based NTHi infections. 
